Matthew Kurian, MD

Thanks to @ASCO for showcasing our insights on ASCO Daily News about the current and future impact of AI on clinical oncology practice. Exciting to collaborate with my mentor and boss @dougflora2 on this important topic! #Oncology #AI #ClinicalPractice dailynews.ascopubs.org/do/future-onco…

Last but not least - @ErikaHamilton9 closes the session with her fun spin on Exciting New Therapies for MBC. An impressive pipeline of innovative agents, attacking breast cancer from all sides: PROTACs, bispecific antibodies, B7H4 ADCs, mutant selective PI3Ki… and more! #IBCE25

Does the Clock Matter in Cancer Care? - Matthew Kurian (@MatthewKurianMD) oncodaily.com/blog/matthew-k… #Health #Oncology #OncoDaily #Medicine #Cancer @CancerWorldmag

I wrote for #ASCOConnection about the duality of oncology—the quiet heaviness of being both oncologist and dad. The weight doesn’t go away, but you get better at carrying it—and finding meaning in the middle of the mess. What keeps you grounded? @ASCO lnkd.in/gxZ5Duuv

I’m sharing an actual recent peer-to-peer call that shows what physicians and patients face when trying to get a surgery approved. This call felt as absurd as it sounds. The peer-to-peer call was to advocate for surgery to prevent and treat lymphedema for a patient with breast…

Every time a radiologist marks key images on an MRI an angel gets its wings

Kidney Cancer 101 Prognosis and Treating Side Effects - 2025 GU Cancers Program youtu.be/iKl-ZCVAMV8?si… via @YouTube In this video, Dr. @MatthewKurianMD discusses potential side effects from kidney cancer treatment, as well as statistics on prognosis. For more, please visit…

The 1st Annual KYSCO Policy Summit 2025 Brought Major Energy to the Bluegrass - Matthew Kurian @MatthewKurianMD oncodaily.com/blog/matthew-k… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #KYSCO2025

#KYSCO2025 is leading efforts for maximzing #oncology team #wellbeing! Thanks to @RayPageDOPhD @MatthewKurianMD for this important session to support the future KY #oncology #workforce @OSSatACCC @ASCO

⭐️My friend @CathyEngMD and I would like to THANK our friends, colleagues, attendees, MEC team, and industry sponsors for making our MLS Nashville 2025 ASCO review a FUN educational event. #Reels David R. Spigel, MD @DavidRSpigel Christine M. Lovly, MD, PhD, FASCO…

Congrats to the ⁦@theNCI⁩ Team on this landmark paper in HLRCC! It sets the SOC in this rare kidney cancer variant. ⁦@NEJM⁩ ⁦@NCICCR_SurgOnc⁩ ⁦@nciccr_gmb⁩ nejm.org/doi/full/10.10…

A new first-line option for metastatic disease. A long awaited goodbye to carbo for stage II disease. A prospective confirmation for the role of HER2DX. And so much more evolution for the HER2+ disease at #ASCO25. Thanks @OncLive for allowing me to review these terrific data.

Remember: it’s only “practice-changing” if, through shared decision-making, our patients discern benefit and are willing to switch or add to their therapies post-#ASCO25 Thanks to @ASCO for these useful after-conference resources 👇🏻

Final results of IMpassion031 by @EMittendorfMD et al. published in @NatureMedicine. Perioperative atezo, added to chemo, led to more favorable survival outcomes for eTNBC. Most pts cleared ctDNA. Poorest outcomes observed for the few pts with RD & ctDNA+. nature.com/articles/s4159…

#AMPLITUDE: role of PARPi in mCSPC? ➡️for fellows: PARPi only approved in mCRPC currently 🚹nira + abi in pts w/ HRRm vs abi in mCSPC 🌀met rPFS; but only 36% in control got PARPi at progression❗️ ❓OS immature, sequencing w/ pluvicto/chemo, long-term AEs: MDS/AML #ASCO25

BMI analysis of ASCENT. Overweight/obese pts experienced higher rates of serious AEs (34% vs 18%) with SG and 41% of obese pts required dose reduction (vs 10%). Should we cap the dose of SG for overweight/obese pts, similar to other ADCs (eg EV, Dato-DXd)? esmoopen.com/action/consume…

Up to 1/3 all TNBCs are diagnosed as stage 1. Many of these pts have an outstanding prognosis, with biomarkers needed to identify them. In this retrospective study, we evaluated sTILs & a 10-gene immune signature among 117 patients 👉100% 5-year RFS if med/high CIG or high sTILs!

Ok the update to the SOFT and TEXT trial is critically important for the general onc community. Please do not put young women on tamoxifen alone as a default. Ovarian suppression and aromatase inhibitor (not tam) is lifesaving. It’s more important than chemo for many #ASCO25

A practice changing trial that IMMEDIATELY needs to be challenged. 2L TDXd only 10%, adj SOC was less than usual, and given PATINA 44mos, a stop-TDXd switch to CDK4/5 + H(P) needs to be explored for QOL. We should not minimize the 48% Fatigue, incld ~8% G3 #ASCO25 @OncoAlert